IDEAYA Biosciences 과거 수익 실적

과거 기준 확인 0/6

IDEAYA Biosciences의 수입은 연평균 -33.1%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 22.1%의 비율로 증가했습니다. 매출은 연평균 18.1%의 비율로 증가해 왔습니다.

주요 정보

-33.1%

수익 성장률

10.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	18.1%
자기자본 수익률	-15.1%
순이익	-4,541.6%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

Aug 25

IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M

Aug 15

수익 및 비용 분석

IDEAYA Biosciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:IDYA 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	4	-178	35	0
30 Jun 24	12	-154	34	0
31 Mar 24	16	-129	30	0
31 Dec 23	23	-113	28	0
30 Sep 23	23	-103	27	0
30 Jun 23	45	-74	26	0
31 Mar 23	47	-68	24	0
31 Dec 22	51	-59	24	0
30 Sep 22	50	-53	23	0
30 Jun 22	29	-66	22	0
31 Mar 22	32	-55	21	0
31 Dec 21	28	-50	20	0
30 Sep 21	36	-37	19	0
30 Jun 21	36	-30	17	0
31 Mar 21	27	-31	17	0
31 Dec 20	20	-34	15	0
30 Sep 20	9	-40	14	0
30 Jun 20	0	-46	13	-17
31 Mar 20	0	-44	11	-8
31 Dec 19	0	-42	10	0
30 Sep 19	0	-40	9	8
30 Jun 19	0	-42	7	37
31 Mar 19	0	-38	6	35
31 Dec 18	0	-34	5	0

양질의 수익: IDYA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IDYA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IDYA 은(는) 수익성이 없으며 지난 5년 동안 연간 33.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IDYA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IDYA 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IDYA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -15.09% )을 갖습니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 03:50
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

IDEAYA Biosciences, Inc. 25 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Madhu Kumar	Baird
Zhiqiang Shu	Berenberg
Justin Zelin	BTIG

IDEAYA Biosciences 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

Consensus revenue estimates decrease by 53%, EPS upgraded

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Consensus revenue estimates fall by 32%

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Consensus revenue estimates increase by 10%

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock.

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

Chief Scientific Officer notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

President notifies of intention to sell stock

Consensus revenue estimates fall by 28%

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Price target increased by 12% to US$49.11

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Principal Accounting Officer notifies of intention to sell stock

Price target increased by 8.2% to US$43.70

Co-Founder notifies of intention to sell stock

Price target increased by 7.7% to US$42.10

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 25%

Price target increased by 7.8% to US$35.08

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Legal Officer & Company Secretary notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

Chief Legal Officer & Company Secretary exercised options and sold US$64k worth of stock

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to US$28.11

Co-Founder exercised options to buy US$160k worth of stock.

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161